SCHEMBL342944

SCHEMBL342944

C[C@@H](O)c1ccccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.55
ADRB1 P08588 2/20 0.55
AOC3 Q16853 1/20 0.50
CYP2D6 P10635 2/20 0.48
NFKB1 P19838 2/20 0.48
HIF1A Q16665 2/20 0.48
BLM P54132 1/20 0.47
PDE2A O00408 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
PNMT P11086 1/20 0.45
NISCH Q9Y2I1 1/20 0.44
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
TSHR P16473 2/20 0.43
ACP3 P15309 1/20 0.42
CASP1 P29466 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316799 1.00 ADRB2 (0.55) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL15943179 1.00 ADRB2 (0.55) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL504837 1.00 ADRB2 (0.55) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL29633572 1.00 ADRB2 (0.55) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL11743000 0.88 ADRB2 (0.46) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL11606505 0.81 TSHR (0.50) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL253300 0.81 ADRB2 (0.52) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL253784 0.81 ADRB2 (0.52) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL253722 0.81 ADRB2 (0.52) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL253301 0.81 ADRB2 (0.52) ADRB2ADRB1AOC3CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117025581-A Double-enzyme ordered immobilization method, product and application thereof 杭州师范大学 2023-11-10 CN claimed
CN-115011574-A Preparation method and application of site-controllable and ordered cross-linked double-enzyme aggregate 杭州师范大学 2022-09-06 CN claimed
CN-104402661-A Economic and efficient method for asymmetric synthesis of R-configuration aromatic alcohol through copper salt catalysis UNIV JIANGNAN 2015-03-11 CN claimed
CN-104388518-A Preparation method of R-1-(2-chlorophenyl)ethanol and its ester WANG TONGJUN 2015-03-04 CN claimed
US-12454530-B2 Amido cyclohexane acid derivatives as LPA receptor inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-10-28 US disclosed
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 US disclosed
US-12428430-B2 Oxabicyclo acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-30 US disclosed
US-12338203-B2 Urea compound for antagonizing LPA1 receptor TAISHO PHARMACEUTICAL CO., LTD. (JP) 2025-06-24 US disclosed
US-20250188068-A1 AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-06-12 US disclosed
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-02-27 US disclosed
WO-2025026266-A1 COMPOUND AS LPAR1 ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 武汉朗来科技发展有限公司 2025-02-06 WO disclosed
US-12139474-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-11-12 US disclosed
US-20090170911-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO. INC (JP) 2009-07-02 US disclosed
US-20090105498-A1 IMPROVED PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYOL)-2-HYDROXY-ETHYL-CARBAMATES JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 US disclosed
US-7517996-B2 Azole compound AJINOMOTO CO., INC. (JP) 2009-04-14 US disclosed
US-20080234525-A1 Ruthenium/iridium complexes; hydrogenation catalysts NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) 2008-09-25 US disclosed
US-20060194850-A1 Novel azole compound AJINOMOTO CO. INC (JP) 2006-08-31 US disclosed
WO-2002069895-A2 HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF SEPRACOR, INC. (US) 2002-09-12 WO disclosed
EP-0198440-B1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2-HALO-1-PHENYL ETHANOL KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1992-08-26 EP disclosed
US-4857468-A BIOSYNTHESIS KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1989-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12338203-B2 Urea compound for antagonizing LPA1 receptor LPAR1, LPAR2, LPAR3 ADRB2 308/4885ADRB1 72/4885AOC3 1368/4885
US-12454530-B2 Amido cyclohexane acid derivatives as LPA receptor inhibitors LPAR1, LPAR2, LPAR3 ADRB2 359/4885ADRB1 168/4885AOC3 1074/4885
US-20090170911-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 ADRB2 486/4885ADRB1 324/4885AOC3 1165/4885
US-12139474-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 ADRB2 842/4885ADRB1 440/4885AOC3 2383/4885
US-12428430-B2 Oxabicyclo acids as LPA antagonists LPAR1, LPAR2, LPAR3 ADRB2 132/4885ADRB1 66/4885AOC3 677/4885
US-20090105498-A1 IMPROVED PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYOL)-2-HYDROXY-ETHYL-CARBAMATES EPM2A, PYGB, KDM1B ADRB2 3003/4885ADRB1 3791/4885AOC3 2638/4885
US-20080234525-A1 Ruthenium/iridium complexes; hydrogenation catalysts ADH5, ADH1A, ADH1C ADRB2 1405/4885ADRB1 1344/4885AOC3 1743/4885
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 ADRB2 311/4885ADRB1 130/4885AOC3 1234/4885
US-20250188068-A1 AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 ADRB2 569/4885ADRB1 238/4885AOC3 1754/4885
US-20060194850-A1 Novel azole compound LPAR1, LPAR2, LPAR3 ADRB2 486/4885ADRB1 324/4885AOC3 1165/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 ADRB2 829/4885ADRB1 442/4885AOC3 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.